# Syndax Pharmaceuticals, Inc. (SNDX) · Edgar & Edgarette company card

> Syndax Pharmaceuticals (SNDX) grew revenue 628% in FY2025 to $172 million, operating margin -158% against a -3.8% median for pharmaceutical preparations, equity 12.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1395937 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SNDX) · [JSON](https://www.pops4.com/boards/company/SNDX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $172M |
| Revenue growth, 1 year | 627.8% |
| Revenue growth per year | 5.4% |
| Operating margin | -158.4% (prior year -1434.4%) |
| Net margin | -165.6% |
| Operating cash flow | −$323M |
| Capital spending | $187,000 |
| Free cash flow | −$323M |
| Cash | $135M |
| Long-term debt | — |
| Total assets | $530M |
| Total equity | $65M |
| Equity ÷ assets | 12.2% |
| Return on equity | -441.6% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -7.54 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; operating loss: a margin of -158.4% in FY2025

## Edgarette's reading

Exposure: revenue $172.4M (FY2025). Experience: revenue up 627.8% on the year, up 5.4% a year over 4 years; operating margin -158.4%, up from -1434.4%. Soundness: equity 12.2% of assets, return on equity -441.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $566.4M and $910.3M next year (method v3, set from 4,309 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -158.4% against a -3.8% median; growth 627.8% against 13.7%.

Range logged 2026-11-03, receipt c2e884fc7bd3dc21, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-11-02 ([filing](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/0001193125-26-443613-index.htm))

## Recent filings

- 10-Q · filed 2026-11-02 · [filing](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443625/0001193125-26-443625-index.htm)
- 8-K · filed 2026-11-02 · 2.02 Results of Operations and Financial Condition; 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/0001193125-26-443613-index.htm)
- 10-Q · filed 2026-08-04 · [filing](https://www.sec.gov/Archives/edgar/data/1395937/000119312526332750/0001193125-26-332750-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/0001193125-26-332736-index.htm)
- 8-K · filed 2026-07-14 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1395937/000119312526302608/0001193125-26-302608-index.htm)
- 8-K · filed 2026-06-10 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1395937/000119312526266027/0001193125-26-266027-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001395937.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1395937

## Cite

POPS4, Edgar & Edgarette: Syndax Pharmaceuticals, Inc. (SNDX) company card, from the company's own SEC filings, accessed 2026-11-03, https://www.pops4.com/boards/company/SNDX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.